[HTML][HTML] Previous COVID-19 infection and antibody levels after vaccination

H Ali, B Alahmad, AA Al-Shammari, A Alterki… - Frontiers in public …, 2021 - frontiersin.org
Background: The emergence of new COVID-19 variants of concern coupled with a global
inequity in vaccine access and distribution has prompted many public health authorities to …

[HTML][HTML] Efficacy, immunogenicity, and safety of COVID-19 vaccines in patients with autoimmune diseases: A systematic review and meta-analysis

A Widhani, AS Hasibuan, R Rismawati, S Maria… - Vaccines, 2023 - mdpi.com
Patients with autoimmune diseases are among the susceptible groups to COVID-19
infection because of the complexity of their conditions and the side effects of the …

Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort

S Ahmed, P Mehta, A Paul, S Anu, S Cherian… - Annals of the …, 2022 - ard.bmj.com
Introduction To assess the incidence and risk factors for breakthrough COVID-19 infection in
a vaccinated cohort of patients with autoimmune rheumatic diseases (AIRDs) and determine …

Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26. COV2. S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative …

T Cerqueira-Silva, JR Andrews… - The Lancet Infectious …, 2022 - thelancet.com
Background COVID-19 vaccines have proven highly effective among individuals without a
previous SARS-CoV-2 infection, but their effectiveness in preventing symptomatic infection …

Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2

C Voutouri, CC Hardin, V Naranbhai… - Proceedings of the …, 2023 - National Acad Sciences
SARS-CoV-2 vaccines are effective at limiting disease severity, but effectiveness is lower
among patients with cancer or immunosuppression. Effectiveness wanes with time and …

[HTML][HTML] Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines

P Kaplonek, Y Deng, JSL Lee, HJ Zar, D Zavadska… - Cell Reports …, 2023 - cell.com
Despite the successes of current coronavirus disease 2019 (COVID-19) vaccines, waning
immunity, the emergence of variants of concern, and breakthrough infections among …

[HTML][HTML] Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

KH Bjørlykke, HS Ørbo, AT Tveter, I Jyssum… - The Lancet …, 2023 - thelancet.com
Background Data on response and safety of repeated vaccinations and hybrid immunity in
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …

Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period

M Bhattacharya, AR Sharma, K Dhama… - International …, 2022 - Elsevier
Hybrid immunity has been accepted as the most robust immunity to fight against SARS-CoV-
2. The hybrid immunity against the virus is produced in individuals who have contracted the …

Omicron surge and the future of COVID-19 vaccinations

E Burhan, R Abi Rachmadi - Medical Journal of Indonesia, 2022 - mji.ui.ac.id
The global surge of Omicron has caused significant concern. Omicron has caused new
wave of infections in nations with adequate vaccine coverage. Omicron has around 30 …

[HTML][HTML] A single dose of ChAdOx1 nCoV-19 vaccine elicits high antibody responses in individuals with prior SARS-CoV-2 infection comparable to that of two-dose …

T Gelanew, A Mulu, M Abebe, TA Bates, L Wassie… - Vaccines, 2022 - mdpi.com
Single-dose COVID-19 vaccines, mostly mRNA-based vaccines, are shown to induce robust
antibody responses in individuals who were previously infected with SARS-CoV-2 …